<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552225</url>
  </required_header>
  <id_info>
    <org_study_id>H 34438</org_study_id>
    <nct_id>NCT02552225</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Laryngitis With Amitriptyline</brief_title>
  <official_title>Double-blind Placebo Controlled Trial of the Treatment of Chronic Laryngitis With Amitriptyline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled trial will compare the effectiveness of&#xD;
      amitriptyline versus placebo (inactive medication) in treating chronic laryngitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic laryngitis commonly manifests through symptoms including cough, hoarseness, throat&#xD;
      clearing, foreign body sensation, throat pain, sensation of excessive phlegm, and difficulty&#xD;
      swallowing. A significant minority also present with GERD, rhinosinusitis-induced post-nasal&#xD;
      drainage, direct allergic effect, and smoking issues.&#xD;
&#xD;
      Amitriptyline is commonly used for mental/mood problems, but is also prescribed to treat&#xD;
      chronic laryngitis because some investigators suggest a neuropathic etiology for idiopathic&#xD;
      chronic laryngitis. No trials have compared any treatment for chronic laryngitis to placebo&#xD;
      and it is unknown if currently used therapies for chronic laryngitis are effective.&#xD;
&#xD;
      At the baseline visit, subjects will be assigned at random to amitriptyline or placebo, which&#xD;
      they will take for 4 weeks each. Subjects will be seen in the clinic at baseline and after 10&#xD;
      weeks. Improvement will be measured using standardized symptom scales, and a self-reported&#xD;
      subjective improvement percentage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding was not obtained so the study could not be continued after the Covid pause.&#xD;
  </why_stopped>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">January 15, 2021</completion_date>
  <primary_completion_date type="Actual">January 15, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Score on Reflux Symptom Index (RSI)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>The Reflux Symptom Index (RSI) is a validated questionnaire consisting of 9 statements to be ranked on a scale of 0-5 (0=no problem, 5=severe problem). RSI scores can range from 0 to 45, with higher scores correlated with more reflux symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Score on the Voice Handicap Index-10 (VHI-10)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>The Voice Handicap Index-10 (VHI-10) is a 10-question scale rated from 0-4 that addresses effects on quality of life from voice disorders (0=never, 1=almost never, 2=sometimes, 3=almost always, 4=always). VHI-10 scores can range from 0 to 40, with lower scores correlated with a higher quality of life related to voice disorders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Score on the Cough Severity Index (CSI)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>The Cough Severity Index is a validated 10 item questionnaire to quantify a patient's symptoms associated with upper airway chronic cough. The 4 point Likert scale for each of the 10 items is 0 to 4 where 0 = Never, 1 = Almost never, 2 = Sometimes, 3 = Almost always, 4 = Always. Scores can range from 0 to 40 and higher scores reflect more coughing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Throat Pain or Burning</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Participants will be asked to rate the severity of their &quot;throat pain or burning&quot; on a scale from 0 (no problem) to 5 (severe). Higher scores are correlated with more throat pain/burning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain When Swallowing</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Participants were asked to rate their pain when swallowing on a scale of 0=none to 5= severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Improvement of Laryngitis Symptoms</measure>
    <time_frame>8 weeks</time_frame>
    <description>Patients will subjectively rate improvement of symptoms on an ordinal 10-point scale where 0=no improvement and 10=significant improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Dropped Out of the Study Due to Side Effects</measure>
    <time_frame>8 weeks</time_frame>
    <description>The number of patients who report they did not continue with study participation due to side effects, will be obtained from study logs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Laryngeal Diseases</condition>
  <arm_group>
    <arm_group_label>amitriptyline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm will receive pills composed only of Avicel (cellulose filler)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amitriptyline</intervention_name>
    <description>Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)</description>
    <arm_group_label>amitriptyline</arm_group_label>
    <other_name>Elavil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects in this arm will receive pills composed only of Avicel (cellulose filler)</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be age 18 or older and able to consent for themselves&#xD;
&#xD;
          2. Must have had structural pathology such as tumor previously ruled out using flexible&#xD;
             laryngoscopy&#xD;
&#xD;
          3. Must be able to speak and read the English language&#xD;
&#xD;
          4. Must have failed a 2 month or longer trial of a proton pump inhibitor for the&#xD;
             treatment of gastro-esophageal reflux&#xD;
&#xD;
          5. Women under 55 years of age who may become pregnant must have a negative pregnancy&#xD;
             test and agree to barrier or hormonal methods of contraception during the study&#xD;
&#xD;
          6. Potential subject and their physician have agreed that amitriptyline will be part of&#xD;
             their regular care plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active untreated environmental allergies&#xD;
&#xD;
          2. Smoking within past 5 years&#xD;
&#xD;
          3. Current upper respiratory infections&#xD;
&#xD;
          4. Use of narcotics (e.g. oxycodone, methadone) within the past week&#xD;
&#xD;
          5. Hypersensitivity to amitriptyline&#xD;
&#xD;
          6. History of amitriptyline use or of other tricyclic antidepressant - including&#xD;
             pregabalin, gabapentin, baclofen, or other gamma-aminobutyric acid (GABA)analogues or&#xD;
             inhibitors - for any medical condition (not limited to chronic laryngitis) within the&#xD;
             past 12 months.&#xD;
&#xD;
          7. Use of any other monoamine oxidase inhibitors (MAOIs) other than amitriptyline within&#xD;
             the past 4 weeks (selegiline, phenelzine, tranylcypromine, isocarboxazid, rasagiline,&#xD;
             phenelzine sulfate, selegiline hydrochloride, rasagiline mesylate, tranylcypromine&#xD;
             sulfate)&#xD;
&#xD;
          8. History of urinary retention&#xD;
&#xD;
          9. History of an acute episode of a major depressive disorder within the past 12 months&#xD;
&#xD;
         10. For women 18-55 years of age without history of menopause: currently nursing or&#xD;
             pregnant, plans to become pregnant, or unwillingness to utilize contraception (barrier&#xD;
             or hormonal methods)&#xD;
&#xD;
         11. Currently participating in another clinical trial that could interfere with the&#xD;
             efficacy of, or participation in, this study.&#xD;
&#xD;
         12. Current untreated diagnosis of gastroesophageal reflux (GERD)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Pieter Noordzij, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <results_first_submitted>September 4, 2021</results_first_submitted>
  <results_first_submitted_qc>October 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2021</results_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>laryngeal sensory neuropathy, chronic laryngeal neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Laryngitis</mesh_term>
    <mesh_term>Laryngeal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amitriptyline</mesh_term>
    <mesh_term>Amitriptyline, perphenazine drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT02552225/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Amitriptyline</title>
          <description>Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)&#xD;
Amitriptyline: Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects in this arm will receive pills composed only of Avicel (cellulose filler)&#xD;
Placebo: Subjects in this arm will receive pills composed only of Avicel (cellulose filler)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amitriptyline</title>
          <description>Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)&#xD;
Amitriptyline: Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects in this arm will receive pills composed only of Avicel (cellulose filler)&#xD;
Placebo: Subjects in this arm will receive pills composed only of Avicel (cellulose filler)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="19.9"/>
                    <measurement group_id="B2" value="55.0" spread="6.6"/>
                    <measurement group_id="B3" value="53.7" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reflux Symptom Index (RSI)</title>
          <description>The Reflux Symptom Index (RSI) is a validated questionnaire consisting of 9 statements to be ranked on a scale of 0-5 (0=no problem, 5=severe problem). RSI scores can range from 0 to 45 with higher scores correlated with more reflux symptoms.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.33" spread="11.50"/>
                    <measurement group_id="B2" value="25.67" spread="6.51"/>
                    <measurement group_id="B3" value="23.50" spread="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Voice Handicap Index-10 (VHI-10)</title>
          <description>The Voice Handicap Index-10 (VHI-10) is a 10-question scale rated from 0-4 that addresses effects on quality of life from voice disorders (0=never, 1=almost never, 2=sometimes, 3=almost always, 4=always). VHI-10 scores can range from 0 to 40, with lower scores correlated with a higher quality of life related to voice disorders.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.67" spread="2.89"/>
                    <measurement group_id="B2" value="9.67" spread="9.5"/>
                    <measurement group_id="B3" value="5.67" spread="7.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cough Severity Index (CSI)</title>
          <description>The Cough Severity Index is a validated 10 item questionnaire to quantify a patient's symptoms associated with upper airway chronic cough. The 4 point Likert scale for each of the 10 items is 0 to 4 where 0 = Never, 1 = Almost never, 2 = Sometimes, 3 = Almost always, 4 = Always. Scores can range from 0 to 40 and higher scores reflect more coughing.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.00" spread="5.66"/>
                    <measurement group_id="B2" value="21.33" spread="12.42"/>
                    <measurement group_id="B3" value="14.40" spread="13.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Throat pain/burning</title>
          <description>Participants will be asked to rate the severity of their &quot;throat pain or burning&quot; on a scale from 0 (no problem) to 5 (severe). Higher scores are correlated with more throat pain/burning.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.0" spread="0.0"/>
                    <measurement group_id="B2" value="3.33" spread="1.53"/>
                    <measurement group_id="B3" value="1.67" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain when swallowing</title>
          <description>Participants were asked to rate their pain when swallowing on a scale of 0=none to 5= severe pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.67" spread="1.15"/>
                    <measurement group_id="B2" value="0.67" spread="0.58"/>
                    <measurement group_id="B3" value="0.67" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Score on Reflux Symptom Index (RSI)</title>
        <description>The Reflux Symptom Index (RSI) is a validated questionnaire consisting of 9 statements to be ranked on a scale of 0-5 (0=no problem, 5=severe problem). RSI scores can range from 0 to 45, with higher scores correlated with more reflux symptoms.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>There was no 8 week RSI score for the participant who withdrew from the amitriptyline arm so the change in score could not be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Amitriptyline</title>
            <description>Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)&#xD;
Amitriptyline: Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in this arm will receive pills composed only of Avicel (cellulose filler)&#xD;
Placebo: Subjects in this arm will receive pills composed only of Avicel (cellulose filler)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score on Reflux Symptom Index (RSI)</title>
          <description>The Reflux Symptom Index (RSI) is a validated questionnaire consisting of 9 statements to be ranked on a scale of 0-5 (0=no problem, 5=severe problem). RSI scores can range from 0 to 45, with higher scores correlated with more reflux symptoms.</description>
          <population>There was no 8 week RSI score for the participant who withdrew from the amitriptyline arm so the change in score could not be calculated.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="1.41"/>
                    <measurement group_id="O2" value="-1.67" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Score on the Voice Handicap Index-10 (VHI-10)</title>
        <description>The Voice Handicap Index-10 (VHI-10) is a 10-question scale rated from 0-4 that addresses effects on quality of life from voice disorders (0=never, 1=almost never, 2=sometimes, 3=almost always, 4=always). VHI-10 scores can range from 0 to 40, with lower scores correlated with a higher quality of life related to voice disorders.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>There was no 8 week VHI-10 score for the participant who withdrew from the amitriptyline arm so the change in score could not be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Amitriptyline</title>
            <description>Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)&#xD;
Amitriptyline: Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in this arm will receive pills composed only of Avicel (cellulose filler)&#xD;
Placebo: Subjects in this arm will receive pills composed only of Avicel (cellulose filler)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Score on the Voice Handicap Index-10 (VHI-10)</title>
          <description>The Voice Handicap Index-10 (VHI-10) is a 10-question scale rated from 0-4 that addresses effects on quality of life from voice disorders (0=never, 1=almost never, 2=sometimes, 3=almost always, 4=always). VHI-10 scores can range from 0 to 40, with lower scores correlated with a higher quality of life related to voice disorders.</description>
          <population>There was no 8 week VHI-10 score for the participant who withdrew from the amitriptyline arm so the change in score could not be calculated.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="11.31"/>
                    <measurement group_id="O2" value="2.67" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Score on the Cough Severity Index (CSI)</title>
        <description>The Cough Severity Index is a validated 10 item questionnaire to quantify a patient's symptoms associated with upper airway chronic cough. The 4 point Likert scale for each of the 10 items is 0 to 4 where 0 = Never, 1 = Almost never, 2 = Sometimes, 3 = Almost always, 4 = Always. Scores can range from 0 to 40 and higher scores reflect more coughing.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>There was no 8 week CSI score for the participant who withdrew from the amitriptyline arm so the change in score could not be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Amitriptyline</title>
            <description>Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)&#xD;
Amitriptyline: Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in this arm will receive pills composed only of Avicel (cellulose filler)&#xD;
Placebo: Subjects in this arm will receive pills composed only of Avicel (cellulose filler)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Score on the Cough Severity Index (CSI)</title>
          <description>The Cough Severity Index is a validated 10 item questionnaire to quantify a patient's symptoms associated with upper airway chronic cough. The 4 point Likert scale for each of the 10 items is 0 to 4 where 0 = Never, 1 = Almost never, 2 = Sometimes, 3 = Almost always, 4 = Always. Scores can range from 0 to 40 and higher scores reflect more coughing.</description>
          <population>There was no 8 week CSI score for the participant who withdrew from the amitriptyline arm so the change in score could not be calculated.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="14.14"/>
                    <measurement group_id="O2" value="3.67" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Throat Pain or Burning</title>
        <description>Participants will be asked to rate the severity of their &quot;throat pain or burning&quot; on a scale from 0 (no problem) to 5 (severe). Higher scores are correlated with more throat pain/burning.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>There was no 8 week assessment of throat pain/burning for the participant who withdrew from the amitriptyline arm, so the change in score could not be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Amitriptyline</title>
            <description>Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)&#xD;
Amitriptyline: Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in this arm will receive pills composed only of Avicel (cellulose filler)&#xD;
Placebo: Subjects in this arm will receive pills composed only of Avicel (cellulose filler)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Throat Pain or Burning</title>
          <description>Participants will be asked to rate the severity of their &quot;throat pain or burning&quot; on a scale from 0 (no problem) to 5 (severe). Higher scores are correlated with more throat pain/burning.</description>
          <population>There was no 8 week assessment of throat pain/burning for the participant who withdrew from the amitriptyline arm, so the change in score could not be calculated.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.83"/>
                    <measurement group_id="O2" value="-1.33" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain When Swallowing</title>
        <description>Participants were asked to rate their pain when swallowing on a scale of 0=none to 5= severe pain.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>There was no 8 week assessment of pain while swallowing for the participant who withdrew from the amitriptyline arm, so the change in score could not be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Amitriptyline</title>
            <description>Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)&#xD;
Amitriptyline: Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in this arm will receive pills composed only of Avicel (cellulose filler)&#xD;
Placebo: Subjects in this arm will receive pills composed only of Avicel (cellulose filler)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain When Swallowing</title>
          <description>Participants were asked to rate their pain when swallowing on a scale of 0=none to 5= severe pain.</description>
          <population>There was no 8 week assessment of pain while swallowing for the participant who withdrew from the amitriptyline arm, so the change in score could not be calculated.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="4.24"/>
                    <measurement group_id="O2" value="0.33" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Improvement of Laryngitis Symptoms</title>
        <description>Patients will subjectively rate improvement of symptoms on an ordinal 10-point scale where 0=no improvement and 10=significant improvement.</description>
        <time_frame>8 weeks</time_frame>
        <population>There was no 8 week assessment of subjective assessment of laryngitis symptoms for the participant who withdrew from the amitriptyline arm, so it could ot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Amitriptyline</title>
            <description>Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)&#xD;
Amitriptyline: Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in this arm will receive pills composed only of Avicel (cellulose filler)&#xD;
Placebo: Subjects in this arm will receive pills composed only of Avicel (cellulose filler)</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Improvement of Laryngitis Symptoms</title>
          <description>Patients will subjectively rate improvement of symptoms on an ordinal 10-point scale where 0=no improvement and 10=significant improvement.</description>
          <population>There was no 8 week assessment of subjective assessment of laryngitis symptoms for the participant who withdrew from the amitriptyline arm, so it could ot be reported.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="0"/>
                    <measurement group_id="O2" value="2.0" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Dropped Out of the Study Due to Side Effects</title>
        <description>The number of patients who report they did not continue with study participation due to side effects, will be obtained from study logs.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amitriptyline</title>
            <description>Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)&#xD;
Amitriptyline: Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in this arm will receive pills composed only of Avicel (cellulose filler)&#xD;
Placebo: Subjects in this arm will receive pills composed only of Avicel (cellulose filler)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Dropped Out of the Study Due to Side Effects</title>
          <description>The number of patients who report they did not continue with study participation due to side effects, will be obtained from study logs.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Amitriptyline</title>
          <description>Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)&#xD;
Amitriptyline: Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects in this arm will receive pills composed only of Avicel (cellulose filler)&#xD;
Placebo: Subjects in this arm will receive pills composed only of Avicel (cellulose filler)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Arm weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Facial weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lack of energy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sleepy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Funding was not obtained so the study could not be continued after the Covid pause.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pieter Noordzij, MD</name_or_title>
      <organization>Boson Medical Center</organization>
      <phone>(617) 414-1756</phone>
      <email>pieter.noordzij@bmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

